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Abstract
The year 2011 was very interesting regarding new studies, trials and guidelines
in the field of lipidology, hypertensiology and nephrology. Suffice it to mention
the new European Society of Cardiology (ESC)/European Atherosclerosis Socie-
ty (EAS) guidelines on the management of dyslipidaemias, American College of
Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines on
hypertension in the elderly, and many important trials presented among oth-
ers during the American Society of Nephrology (ASN) Annual Congress in
Philadelphia and the AHA Annual Congress in Orlando. The paper is an attempt
to summarize the most important events and reports in the mentioned areas
in the passing year.
K Ke ey y   w wo or rd ds s: :   anaemia, blood pressure, dyslipidaemia, hypertension, lipids, renal dis-
ease, transplantation.
Lipidology update 2011
Cardiovascular disease (CVD) due to atherosclerosis and thrombosis is
the foremost cause of premature mortality and drop in disability-adjust-
ed life years in Europe, and is also increasingly common in developing
countries [1, 2]. The main clinical entities are coronary artery disease (CAD),
ischaemic stroke, and peripheral arterial disease (PAD) [3]. This year, new
joint European Society of Cardiology (ESC)/European Atherosclerosis Soci-
ety (EAS) guidelines on the management of dyslipidaemias have been
issued [4]. The most important and somewhat novel aspects identified by
the task force were the following: (1) treatment of dyslipidaemia should
not be considered as an isolated process, but rather within the context of
integrated prevention of CVD in an individual patient. The SCORE scale is
recommended as a basic tool for calculating CV risk; (2) therapeutic objec-
tives: strengthening of strict low-density lipoprotein cholesterol (LDL-C)
targets for patients with very high, high, and intermediate risk levels (no
longer as an optional criterion) [4-7]; (3) non-pharmacological therapies:
the relevance of diet and exercise not just in the reduction of total risk,
but also in the specific treatment of dyslipidaemias [4, 8]; (4) lipid-lower-
ing drugs: a logical emphasis on statins as an essential treatment for car-
diovascular prevention, and scarce details on fibrates, niacin, and absorp-
tion inhibitors; (5) dyslipidaemia treatment in special clinical situations:
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the detailed description of targets and prescriptions
in several situations and subgroups [4, 9, 10].
The ESC/EAS guidelines were highly anticipated,
but there are still many questions remaining [4].
The guidelines do not give the answer how to pro-
ceed with patients in many clinical situations, e.g.
with high-risk patients and a low level of high-den-
sity lipoprotein cholesterol (HDL-C), and they only
describe very general conditions, such as patients
with metabolic syndrome or acute coronary syn-
drome [4]. They also do not give detailed recom-
mendations on combined therapy in lipid disorder
patients, which seems to be a future method of
dyslipidaemia treatment, for example in patients
with chronic kidney disease (CKD). The recent Study
of Heart and Renal Protection (SHARP) trial with
simvastatin and ezetimibe showed 17% reduction
in major atherosclerotic events and 15.3% in major
vascular events in CKD [4, 11, 12]. 
The new guidelines continue to recognize that
elevated levels of total cholesterol and LDL-C are
the most important lipid disorders in terms of prog-
nosis as well as the quantity of available epidemi-
ological, pathological, and therapeutic data that
exist [4]. Also, much more attention needs to be
paid to changing treatment of patients to achieve
target levels. In one of the trials Mark et al. report-
ed a higher percentage of 12 317 high-risk patients
achieving LDL-C targets when treated by special-
ists compared with those followed up by GPs (43%
vs. 32%, respectively; p < 0.0001) [13, 14]. The
impact of this effect is likely to increase as more
statins (and other lipid-lowering drugs) become
generic. The authors also specified that the use of
combination therapy (e.g. statin plus ezetimibe)
contributed to better goal achievement [13, 14]. This
interpretation is in agreement with community-
based studies that showed a significantly improved
outcome in lipid targets following the addition of
ezetimibe to a statin [15-17].
Higher doses of statins in monotherapy repre-
sent another therapeutic option, although this may
be associated with an increased risk of adverse
effects [18, 19]. With regard to safety, the primary
document mentions that the majority of statins,
with the exception of pravastatin, rosuvastatin, and
pitavastatin,  are  significantly  metabolized  by
cytochrome P450, which could provide an advan-
tage in terms of safety [18-20]. The safety of statins
is also independent of the treatment duration [20].
Additionally, statins could be used in patients with
renal failure, since these compounds are preferen-
tially eliminated through the hepatic pathway (flu-
vastatin, atorvastatin, and pitavastatin) [18]. It is,
however, worth mentioning that recently, accord-
ing to the results of the Study of the Effectiveness
of Additional Reductions in Cholesterol and Homo-
cysteine (SEARCH) trial, the Food and Drug Admin-
istration (FDA) released an alert regarding the
increased risk of myopathy and rhabdomyolysis
with 80 mg doses of simvastatin [21]. However, the
recent studies with other statins (atorvastatin, rosu-
vastatin) have not given similar results [22]. 
The recent data have also revealed that statin
therapy might be associated with an increased risk
of developing diabetes. A meta-analysis of the most
major placebo and standard care-controlled statin
trials with more than 90,000 participants confirmed
that statin therapy was associated with a 9%
increased risk of developing diabetes [23]. Newly
published data have confirmed a dose-dependent
effect, with 12% higher risk of developing diabetes
on intensive-dose statin therapy compared with
moderate-dose therapy [24]. In this meta-analysis,
one additional patient developed diabetes for every
three patients protected from a major cardiovas-
cular event [24]. The observation of higher diabetes
risk remains unexplained at present, although stud-
ies in animal models suggest the possibility of
impaired peripheral insulin signalling induced by
statins [25]. Cardiovascular benefits of statin ther-
apy clearly outweigh the risk of developing diabetes,
but the data suggest the need to make patients
aware of this possible risk and to monitor patients
for development of diabetes, especially on inten-
sive-dose therapy [4, 26-28]. On the other hand, we
urgently need well-designed statin clinical trials
with new onset diabetes as a main endpoint, in
order  to  finally  answer  the  question  on  the
increased risk of carbohydrate disturbances as an
effect of statin therapy [29].
The current guidelines recommend wide pre-
scription of statins, even the highest allowable or
tolerable doses, in order to reach LDL-C goals [4].
For patients with statin intolerance, the recom-
mendation is for bile acid chelating agents or
niacin, although this was published before the
Athero  thrombosis Intervention in Metabolic syn-
drome with low HDL/high triglycerides: impact on
Global Health outcomes (AIM-HIGH) study was
prematurely terminated due to lack of effective-
ness of this treatment (extended-release niacin –
500-2000 mg per day) and unexplained increase
in ischaemic stroke [30, 31]. Absorption inhibitors
are not recommended with much zeal, although
they are mentioned in possible association with
low doses of statins in patients whose poor tol-
erance impedes prescribing an adequate statin
dose, as well as with bile acid chelating agents or
niacin [4].
Therapeutic interventions should be aimed not
only  at  lowering  ApoB-containing  fractions  of
lipoproteins, but also at increasing HDL-C, especially
when there is a trend to decrease the number of
patients with HDL-C above 46 mg/dl (1.2 mmol/l)
in women and 40 mg (1.0 mmol/l) in men – 56% toArch Med Sci 6, December / 2011 1057
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50.1% when comparing the NATPOL 2002 and 2011
registries respectively [32]. 
Some  of  the  already  used  pharmacological
agents such as niacin, fibrates and statins present
various mechanisms of protection from the dele-
terious effects of chronic inflammation on HDL
functionality. However, a need for a novel thera-
peutic approach has emerged, in order to prevent
or restrain the transformation of native HDL into
dysfunctional HDL. Testing new agents which atten-
uate atherosclerosis in dyslipidaemic patients, such
as  cholesterylester  transfer  protein  (CETP)
inhibitors, rHDL, Apo A-I Milano, and Apo-mimetic
peptides, is giving promising results [33-37]. It
seems that the year 2011 was especially advanta-
geous for CETP inhibitors. The dal-VESSEL study
showed that only 4 weeks of dalcetrapib 600 mg
daily caused a significant increase (by 31%) in HDL-C
(HDL2-C to a greater extent than HDL3-C) and Apo
A-I levels, without increasing blood pressure and
without impairing endothelial function [38]. The dal-
PLAQUE study additionally showed reduction in vas-
cular inflammation and a decrease in adverse struc-
tural  vascular  changes  in  subjects  receiving
dalcetrapib [39]. 
Still there are no clear data dealing with statin
use in elderly patients, particularly those with
depression, dementia and multiple falls. Myalgia
and myopathy following statin use may be partic-
ularly troublesome in that population. Most statin-
related muscle symptoms occur in people with some
predisposition (e.g. low level of blood vitamin D)
and are often related to strenuous exercise. Inter-
ference with other drugs (calcium channel block-
ers, azoles or macrolides) may increase myotoxic
effects of statins [35, 36]. Additionally, Newson et al.
[40] found that higher total cholesterol and non-
high-density lipoprotein cholesterol in older per-
sons was associated with a lower risk of non-car-
diovascular and total mortality. In part, this was
attributable to a lower risk of cancer deaths [40].
We are still waiting for new Adult Treatment Pan-
el (ATP) IV guidelines, which may answer some of
the above questions. The publication of the rec-
ommendations is expected for public review and
comment, with an expected release date in 2012
(probably in the second half). 
Hypertension update 2011
According to the cardiovascular continuum the-
ory, lipid disorders and hypertension lead to ather-
osclerosis progression and next to CAD and its com-
plications – acute coronary syndrome, heart failure
(HF) and sudden cardiac death [32, 41, 42]. Coro-
nary artery disease is also related to endothelial
dysfunction [43, 44]. Over the last years, several
studies have suggested that some factors, e.g.
endothelin-1, C-reactive protein (CRP), dimethy-
larginine, haptoglobin polymorphism, transforming
growth factor ʲ (TGF-ʲ), heat shock protein 70
(HSP70), plasma nitric oxide (NO) and vascular
endothelial growth factor (VEGF), could be markers
of risk for endothelial dysfunction and have an
impact on long-term prognosis in patients with CAD
[45-55]. Some studies showed that proton pump
inhibitor based therapy may have beneficial effects
in patients with CAD. The 14-day therapy with
a double dose of rabeprazole (open-label trial) [56]
or omeprazole (randomized, placebo-controlled
cross-over trial) [57] may lead to a decrease in the
number of total chest pain episodes and in some
electrocardiographic signs of myocardial ischaemia
in patients with stable angina pectoris and CAD.
Another trial showed that treatment with a double
dose of omeprazole increases endorphin plasma
level in patients with coronary artery disease [58].
The goal of antihypertensive therapy is to abol-
ish the risks associated with blood pressure (BP)
elevation without adversely affecting quality of life
[59]. Drug selection is based on efficacy in lower-
ing BP and in reducing CV endpoints, including
stroke, myocardial infarction, and heart failure [60].
Clinical trials document that achieving BP targets
is usually not possible with a single agent [60, 61].
In the Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT), only
26% of patients achieved goal BP with monother-
apy [62]. In the Hypertension Optimal Treatment
(HOT) trial, 33% of patients achieved their BP tar-
get (diastolic only) with monotherapy, 45% required
2 drugs, and 22% needed ≥ 3 agents [63]. It is rec-
ommended to routinely use combination therapy
to achieve BP targets, to use only preferred or
acceptable 2-drug combinations and to initiate com-
bination therapy in patients who require ≥ 20/
10 mmHg reduction to achieve target BP [60]. 
In October 2009, the European Society of Hyper-
tension (ESH) presented its updated recommen-
dations, which were important in many respects
[64, 65]. However, after almost 2 years since the
publication, there are still many issues to be solved.
Despite continuously accumulating data, many deci-
sions on hypertension management are still made
without the support of evidence from the available
clinical trials. For example, we still do not know the
optimal strategy for dealing with patients with
stage 1 hypertension, and there is uncertainty about
whether subjects with BP in the range 140-149/
90-99 mmHg would benefit from antihypertensive
treatment [66-68]. Moreover, data from the avail-
able clinical trials do not support the view that low-
ering BP below 130 mmHg in high-risk patients 
provides an additional benefit, which might be con-
nected with the J-curve phenomenon, observed par-
ticularly in patients with hypertension and diabetes
and/or CAD (and probably also with ventricular 1058 Arch Med Sci 6, December / 2011
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dysfunction) [69-71]. Since the publication of the
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (JNC 7) guidelines (2003)
[72], there has also been much discussion whether
we should treat high-risk patients with high nor-
mal BP (with prehypertension), although the cur-
rent ESH guidelines do not recommend such ther-
apy [64, 73-75].
Hypertension therapy in elderly patients is anoth-
er important issue [76], which had been controver-
sial until the results of the Hypertension in the Very
Elderly Trial (HYVET) were published [77]. Hyperten-
sion in elderly people is a major risk factor for coro-
nary events, stroke, heart failure, and peripheral arte-
rial disease [78-81]. Compared with younger patients
with hypertension, the prevalence of target organ
damage and clinical CVD is significantly higher in
the elderly, as is the incidence of new CV events [76].
However, despite this increased risk, elderly patients
have the lowest rate of BP control [82, 83]. This has
been recently confirmed in the PolSenior registry in
patients aged > 65 years, which showed that ele-
vated blood pressure exists in 76% of patients (72%
of men and 78% of women), and in only 25% of
patients is well controlled [83]. 
In April 2011, new American College of Cardiolo-
gy Foundation (ACCF)/American Heart Association
(AHA) guidelines on hypertension in the elderly
were published [84]. According to them the initial
antihypertensive drug therapy should be started at
the lowest dose and gradually increased, depend-
ing on the BP response to the maximum tolerated
dose [84]. If the antihypertensive response to the
initial drug is inadequate after reaching the full
dose, a second drug from another class should be
added, provided the initial drug is tolerated [84, 85].
ACCF/AHA guidelines confirm the current ESH [64]
and current NICE recommendations [84] that all
main antihypertensive drug classes – diuretics,
angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin-receptor blockers (ARBs), calcium chan-
nel blockers (CCBs), and ʲ-blockers – have shown
significant benefits in reducing CV outcomes in ran-
domized  trials  among  elderly  persons  [86-91].
Where possible, a combination therapy should be
the method of choice [84, 85].
The current ACCF/AHA recommendations still
raise some important questions regarding hyper-
tension treatment in the elderly [84]. It is crucial to
finally establish BP values for making the diagno-
sis of hypertension as well as setting targets for
treatment. The most practical definition of hyper-
tension in the elderly should describe a BP level
above which medical intervention (lifestyle changes
or drugs) might be expected to provide significant
clinical benefits. It is also important to identify
which drugs will be most effective for reducing CV
events [84]. However, especially in these patients,
we should be very careful to avoid intensive low-
ering of BP, as this might be poorly tolerated and
might increase CV events – the J-curve phenome-
non [69]. Probably only the forthcoming studies,
including the Systolic Blood Pressure Intervention
Trial (SPRINT) [91] and ESH-SCHL-SHOT (Stroke in
Hypertension Optimal Treatment trial of the Euro-
pean Society of Hypertension) [69], will provide the
data to establish clear guidelines on the optimal
target BP level for these patients [93]. 
According to all the current hypertension guide-
lines, it is recommended to look for the best diag-
nostic methods in order to effectively prevent sub-
clinical organ damage (SOD) [64, 84, 85]. Genetic
variability and/or some biomarkers can be valuable
diagnostic and prognostic tools [93-103]. Although
there are numerous studies investigating biomark-
ers in heart failure (HF), there are relatively few that
relate them to HF in hypertensive patients. This is
vital as hypertension is considered to be one of the
main predictors of HF. Prolonged hypertension has
been shown to cause left ventricular (LV) structur-
al remodelling, cardiac function alterations and
chronic heart failure (CHF) [104-107]. There are often
no signs of CAD on an electrocardiographic stress
test with no change in epicardial coronary vessels
on coronary angiography [64, 108]. Therefore, it is
important to establish a panel of diagnostic tests
in patients with hypertension to enable the early
detection of abnormalities before the occurrence
of symptoms and thus allow the implementation
of optimal treatment [64, 84]. Elevations in inflam-
matory markers, not observed in isolated hyper-
tension, become evident in the presence of target
organ damage [109-112]. Raised levels of high-sen-
sitivity CRP (hs-CRP) and myeloperoxidase (MPO)
have been suggested as markers of HF in hyper-
tensive patients [113]. Although a lack of significant
correlation between log-transformed hs-CRP and
MPO was observed, combined analysis of these 
2 parameters revealed a 6-fold increased risk of HF
(p < 0.01) when both markers were elevated [114,
115]. According to the authors, concurrent hs-CRP
and MPO measurements may be of distinct and
complementary prognostic value in patients with
chronic systolic HF [113-115].
Biomarkers, such as natriuretic peptides, have
been suggested to be useful in determining the
severity of disease and prognosis of clinical out-
comes in patients with acute HF [116, 117]. Brain
natriuretic peptide (BNP), a neurohormone syn-
thesized in ventricular myocardium, is released into
the circulation in response to ventricular dilatation
and pressure overload [118, 119]. The plasma level
of BNP is considered to be a powerful marker for
cardiac dysfunction and a useful prognostic indi-
cator in patients with critical CV diseases [120-122].Arch Med Sci 6, December / 2011 1059
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It seems that some answers may be provided by
the Eighth Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (JNC 8) and the European
Society of Hypertension 2012 guidelines, which are
to be released by the end of 2012. 
Hypertension and kidney diseases update 2011
Concerning hypertension and kidney diseases
there is evidence that a low sodium diet (in patients
with proteinuric kidney disease treated with lisino-
pril) (The HOlland NEphrology Study – HONEST tri-
al) reduced mean arterial blood pressure from 134
mmHg at baseline to 123 mmHg, whereas addition
of valsartan to either a regular or low salt diet
resulted in a decrease in mean blood pressure by
only 2-3 mmHg [123]. Moreover, two meta-analyses
presented the data from randomized controlled tri-
als on salt restriction and cardiovascular mortality.
Taylor et al. [124] analyzed the effect of sodium
restriction on the blood pressure status at baseline
(normotensive vs hypertensive). They found a ten-
dency to better cardiovascular outcomes when
patients were salt-restricted [124]. He et al. [125]
reported that sodium restriction was associated
with significant reduction in cardiovascular events
but not in mortality. In most patients with hyper-
tensive nephropathy and a low glomerular filtration
rate  (GFR),  the  kidney  function  progressively
declines despite adequate control of the hyper-
tension with angiotensin-converting enzyme inhi-
bition [125]. Mahajan et al. [126] found in a 5-year,
prospective, randomized, placebo-controlled, and
blinded interventional study that daily oral sodium
bicarbonate slowed GFR decline in patients with
hypertensive nephropathy with reduced but rela-
tively preserved estimated GFR (eGFR) (mean 75
ml/min). The authors concluded that in hyperten-
sive nephropathy, daily sodium bicarbonate was an
effective nephroprotective adjunct to blood pres-
sure control with angiotensin-converting enzyme
inhibition [126].
There are two major challenges in the treatment
of resistant hypertension. In the Rheos Pivotal Tri-
al [127], surgical implantation of a device designed
to stimulate the carotid baroreceptors resulted, dur-
ing a 6-month period, in a non-significant decrease
in systolic blood pressure and significant achieve-
ment of target systolic blood pressure of 140 mmHg
or lower [127]. Other potentially effective therapies
in the treatment of resistant hypertension include
catheter-based radiofrequency ablation of the renal
sympathetic nerves. In the Symplicity-HTN-2 trial it
was reported that 6 months after the procedure
a significant fall in blood pressure was found in
patients with resistant hypertension treated so far
with an average of five hypotensives including
diuretics [128]. During the American Society of
Nephrology Congress, held in Philadelphia during
8-13.11.2011, in the Hot Topics Session, Prof. Gerald
Frederic Dibona questioned the long-term efficacy
and safety of this procedure (personal communi-
cation). Medical evaluation was performed only in
64 patients 12 months after and in 18 patients 
24 months after the radiofrequency ablation. The
number of antihypertensives remained the same
as at the baseline [129]. 
Nephrology 2011 update
Focal and segmental glomerulosclerosis has
become  an  important  lesion  underlying  the
nephrotic syndrome. There are several morpholog-
ical variants found in light microscopy, but all share
podocyte pathology ultrastructurally [130]. Primary
focal segmental glomerulosclerosis (FSGS) is one
the causes of nephrotic syndrome, and injury to
glomerular cells, including podocytes, may be due
to a circulating toxin [130-132]. However, Wei et al.
[131] reported that serum soluble urokinase recep-
tor (suPAR) could be a possible cause of primary
FSGS. They found that in 78 patients with FSGS
suPAR was significantly higher than in patients with
other glomerular disease and healthy volunteers.
Moreover, the highest suPAR levels were in pre-
transplant sera of patients who developed recur-
rent FSGS after transplantation [131]. The probable
mechanism of FSGS by suPAR is the activation of
ʲ3 integrin in podocytes. In an animal model the
selective expression of suPAR was associated with
progressive  glomerulopathy  with  histological
changes characteristic of FSGS [129]. In the treat-
ment of steroid-resistant primary FSGS multicenter
clinical trial (FSGS-CT) there was no difference
between patients treated with mycophenolate
mofetil and oral dexamethasone vs. cyclosporine
in regard to achieving sustained remission [133].
The limitation of the study is the small sample size:
of the projected 500 patients only 138 were ran-
domized. Olson et al. [134] found that patients with
anti-GBM (anti-glomerular basement membrane)
disease may develop low titres of anti-neutrophilic
cytoplasmic antibodies (ANCA) years before the clin-
ical symptoms and months prior to synthesis of
anti-GBM antibodies. In idiopathic membranous
nephropathy the phospholipase A2 receptor was
recently identified as a major target antigen [135].
Circulating antibodies against PLA2R were found in
70-80% of patients with idiopathic, but not in sec-
ondary membranous nephropathy or other kidney
diseases. Beck et al. [136] reported that a decline in
anti-PLA2R  antibodies may predict  the  clinical
response to rituximab treatment.
Lysosomal membrane protein 2 (LAMP2) is a tar-
get of ANCA antibodies, in addition to more com-
monly known targets proteinase 3 and myeloper-
oxidase.  Roth  et  al. [137]  however  found  no1060 Arch Med Sci 6, December / 2011
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correlation between LAMP2 titres and disease activ-
ity. Their data do not support a mechanistic rela-
tionship between anti-LAMP-2 antibodies and ANCA
glomerulonephritis. During the American Society of
Nephrology (ASN) Congress in November 2011,
Prof. Glassock insisted on more detailed study in
membranoproliferative glomerulonephritis (MPGN),
as only 10% are really idiopathic (personal commu-
nication). Most cases of MPGN are secondary in the
course of immune complex diseases (lupus ery-
thematosus [LE], cryoglobulinaemia, chronic HCV
infection, paraproteinaemia), disorders of comple-
ment regulation, thrombotic microangiopathy, and
paraprotein deposition e.g. monoclonal gammopa-
thy. The most common complement related disease
with MPGN is atypical haemolytic uraemic syn-
drome (HUS), which may be caused by inherited
(often familial) polymorphism of factor H – a down-
regulating component of the complement system
– or acquired antibodies against factor H. Finding
a primary cause of MPGN may have a paramount
effect on its proper therapy [137, 138]. 
A novel strain of Escherichia coli O104:H4 bacte-
ria caused a serious outbreak of food-borne illness
focused in northern Germany in May to June 2011.
The illness was characterized by bloody diarrhoea,
with a high frequency of serious complications,
including HUS, a condition that requires urgent
treatment. The outbreak was originally thought to
have  been  caused  by  an  enterohaemorrhagic
(EHEC) strain of E. coli, but it was later shown to
have been caused by an enteroaggregative E. coli
(EAEC) strain that had acquired the genes to pro-
duce Shiga toxins [139]. On 30 June 2011 the Ger-
man  Federal  Institute  for  Risk  Assessment
announced that seeds of fenugreek imported from
Egypt were likely the source of the outbreak [140].
While HUS is usually seen in children under the age
of 6 years, the recent outbreak affected mostly
(87%) individuals above the age of 20 years [141].
Therapeutic plasma exchange was the mainstay of
therapy. Almost at the same time, it was reported
that eculizumab, a monoclonal antibody inhibiting
the terminal complement cascade and already
approved for paroxysmal nocturnal haemoglobin-
uria, was able to cure the severe neurological symp-
toms of three children with HUS [142]. Eculizumab,
a first-in-class  terminal  complement  inhibitor,
specifically targets uncontrolled complement acti-
vation, and is also indicated for the treatment of
patients with atypical HUS (aHUS) to inhibit com-
plement-mediated thrombotic microangiopathy
(TMA), although it is off-label use of this drug (it
awaits registration for this indication in Europe,
while in September 2011, the FDA granted acceler-
ated approval for use in aHUS). We have to bear in
mind  that  this  treatment  is  associated  with
enhanced risk of viral infections, and meningococ-
cal vaccination is recommended in patients with
complement deficiencies [142, 143]. 
Recently, Roccatello et al. [144] reported that
intensive administration of rituximab combined
with low doses of intravenous cyclophosphamide
and methylprednisolone pulses followed by a rapid
tapering of prednisone to 5 mg/day as a sole main-
tenance therapy was able to induce long-term
remissions in patients with severe systemic lupus
erythematosus (SLE) and major organ involvement.
However, we have to be aware that rituximab is an
off-label drug in patients with severe SLE (with or
without nephritis) who are intolerant of conven-
tional therapy and need alternative therapeutic
options, and look carefully for long-term adverse
events occurring mainly months after its adminis-
tration [144]. 
D Di ia ab be et ti ic c   k ki id dn ne ey y   d di is se ea as se e   
Despite treatment, diabetic kidney disease is the
leading cause of end-stage kidney disease in the
developed world [145, 146]. There is an urgent need
for new approaches to prevent progression of dia-
betic kidney disease. On the horizon there has
appeared bardoxolone methyl, an oral modulator
of Nrf2 (nuclear factor erythroid-2-related factor 2),
which with its negative regulator KEAP1 (Kelch-like
ECH-associated protein 1) triggers cytoprotective
responses affecting over 300 genes encoding detox-
ification, antioxidant and anti-inflammatory mole-
cules [147]. Expression of Nrf2 is increased in the
diabetic kidney in parallel to increased levels of
reactive oxygen species and activation of nuclear
factor ʺB. Several putative Nrf2 activators are
shown to have renoprotective effects in experi-
mental diabetes such as sulforaphane (found in
Brassica species, e.g. broccoli), diallyl sulfides (found
in garlic, chives, and onion), curcumin (turmeric)
and caffeic acid phenethyl ester (many plants and
honey) due to the attenuation of vascular damage
in hyperglycaemia [147]. A selective activator of
Nrf2, bardoxolone methyl, was found to increase
estimated GFR by 5-10 ml/min/17.73 m2 in patients
with type 2 diabetes mellitus and impaired kidney
function, i.e. eGFR between 20 and 45 ml/min per
1.73 m2 (BEAM trial) [147]. Bardoxolone methyl
increased eGFR within 4 weeks of the treatment
and the improvements at each dose (75 mg and
150 mg qd) were sustained during the 1 year of
active treatment when compared to placebo. Upon
withdrawal of bardoxolone methyl, kidney function
returned to the baseline [147]. The proposed mech-
anisms include Nrf2 activation leading to an antiox-
idant response via regulatory domains of the tar-
get genes. It may also increase the expression of
haem oxygenase (known to inhibit directly or indi-
rectly tubuloglomerular feedback by reducing super-
oxide) in renal tubules. Reduction in superoxideArch Med Sci 6, December / 2011 1061
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leads to diminished afferent arteriolar vasocon-
striction and subsequently to a rise in GFR. Bar-
doxolone  methyl  also  affects  muscle  (muscle
cramps are a major side effect); therefore we may
also presume that it may affect creatinine metab-
olism [147]. However, 24-h creatinine clearance
increased upon bardoxolone methyl treatment and
serum urea was diminished. On the other hand,
albuminuria significantly increased in bardoxolone
methyl-treated patients. Studies on cystatin C or
isotope GFR should be performed to further clarify
the issue of the fall in serum creatinine and a rise
in  eGFR  in  patients  treated  with  bardoxolone
methyl [147]. In 2013 the results of the Bardoxolone
methyl EvAluation in patients with Chronic kidney
disease and type 2 diabetes: the Occurrence of
renal eveNts (BEACON) trial on the effects of bar-
doxolone methyl in a much larger population of
type 2 diabetic patients should be available.
D Di ia al ly ys si is s   
Secondary  hyperparathyroidism  (SHPT)  is
a major complication in patients with CKD and
intact parathyroid hormone (iPTH) control remains
an important therapeutic goal. Cinacalcet, a cal-
cimimetic, is approved for the treatment of SHPT
in patients with CKD 5D. Paricalcitol, a selective vita-
min D receptor activator, is approved for the treat-
ment of SHPT in patients with CKD 3, 4, and 
5 including 5D (dialysis) [148, 149]. During both the
ASN Congress and the ERA-EDTA Congress in 2011,
results of the IMPACT-SHPT study (international ran-
domized phase IV open-label multi-centre study)
comparing the safety and efficacy of paricalcitol
and cinacalcet to determine the most effective ther-
apy for the treatment of SHPT in 272 subjects
undergoing haemodialysis were presented. The
study was divided into an Oral and IV (intravenous)
Stratum. Patients received either paricalcitol (ini-
tial dose of 0.07 ﾵg/kg in the IV Stratum and
PTH/80 in the Oral Stratum) and additive cinacal-
cet for hypercalcaemia or cinacalcet (30 mg initial
dose) plus low-dose vitamin D for 28 weeks [150].
Overall, during 21-28 weeks of the treatment, reduc-
tion of ≥ 30% and ≥ 50% in baseline iPTH was
achieved in 78% and 65% of subjects treated with
paricalcitol as compared with 50% and 36% of sub-
jects receiving cinacalcet-based treatment. How-
ever, in the IV stratum, paricalcitol was superior to
cinacalcet  in  achieving  primary  efficacy,  with
a mean iPTH value of 150-300 pg/ml during the
evaluation period (paricalcitol = 57.7% and cinacal-
cet = 32.7%; p = 0.016) [150]. In the oral stratum,
paricalcitol and cinacalcet were similarly effective.
The proportion of hypercalcaemia (Ca > 10.5 mg/dl)
in the paricalcitol group was low (4 out of 69) (only
in IV stratum) whereas a higher proportion in the
cinacalcet group (27 of 59) experienced hypocal-
caemia (Ca < 8.4 mg/dl) [151]. Additionally, total
SHPT medication costs were 40% lower in the par-
icalcitol arm compared with the cinacalcet arm.
However, the costs were calculated based on the
American wholesale pricing (with various cinacal-
cet and vitamin D preparations and IV paricalcitol
preparations); therefore, this analysis must be
regarded as preliminary and should not be extrap-
olated to the European market [151]. 
On the other hand, data from the ADVANCE 
(A randomiseD VAscular calcificatioN study to evalu-
ate the effects of CinacalcEt) study (prospective,
randomized, controlled trial comparing the pro-
gression of vascular and cardiac valve calcification
in 360 prevalent adult haemodialysis patients with
secondary hyperparathyroidism treated with either
cinacalcet plus low-dose vitamin D sterols or flexi-
ble doses of vitamin D sterols alone) were also pub-
lished in 2011. Raggi et al. [152] demonstrated that
91% of the patients studied had calcification of the
thoracic aorta, 50% had mitral valve calcification,
and 46% had aortic valve calcification at baseline.
The estimated rate of progression of calcifications
was 14.3% lower in the cinacalcet plus low-dose
vitamin D group (95% CI: –23.1%, –4.5%) (p = 0.006)
[152]. Using Agatston scores, the percent change in
these scores for the thoracic aorta, the aortic and
mitral valve were nominally less in the cinacalcet
plus low-dose vitamin D group than in the flexible
vitamin D group; however, using volume scores the
differences between groups were significant at the
aortic valve. The authors suggested that cinacalcet
plus low-dose vitamin D sterols may attenuate 
vascular and cardiac valve calcification in patients
on haemodialysis with moderate to severe SHPT
[152]. The results from the ongoing EVOLVE (Evalu-
ation of Cinacalcet Therapy to Lower Cardiovascu-
lar Events) study [153], designed to determine
whether cinacalcet can reduce the exceptionally
high rates of mortality and cardiovascular events
among patients on haemodialysis, are eagerly
awaited [153]. 
After the publication of the Trial to Reduce Car-
diovascular Events With Aranesp Therapy (TREAT)
trial [154] the US Food and Drug Administration
(FDA) modified its indications for the treatment of
renal  anaemia  with  erythropoietin  stimulating
agents (ESA) [155]. According to the revised indica-
tion, ESA therapy should be considered when the
haemoglobin level is less than 10 g/dl in CKD and
dialysed  patients.  Erythropoietin  stimulating 
agents dose should be reduced or ESA should be 
withdrawn when haemoglobin exceeds 10 g/dl in
CKD patients and approaches or exceeds 11 g/dl in
dialysed patients [155-158]. During ASN Prof. Par-
frey presented new guidelines on anaemia treat-
ment; however, it is anticipated that these guide-
lines will be published in early 2012 (KDIGO Clinical1062 Arch Med Sci 6, December / 2011
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Practice Guideline on Anemia in CKD, chaired by
Drs. John McMurray and Patrick Parfrey).  
According  to  Foley  et  al. [159],  patients
haemodialysed thrice weekly are more likely to die
on the day following the long interval (over a week-
end) relative to other days. These data were based
on the retrospective analysis of the End Stage Renal
Disease Clinical Performance Measures Project,
involving 32,065 haemodialysed patients [159]. In
the secondary analysis of the Hemodialysis (HEMO)
study (1426 patients) it has been shown that
hypotensive episodes during a haemodialysis ses-
sion were associated with increased risk of arteri-
ovenous fistula thrombosis [160].
T Tr ra an ns sp pl la an nt ta at ti io on n
Despite use of new immunosuppressive regi-
mens, e.g. with belatacept, no milestone in graft
survival or patient survival was reported [161-165].
Montgomery et al. [166] reported that a desensiti-
zation protocol (for patients with preformed HLA
antibodies) with intravenous immunoglobulin (IVIG)
combined with plasmapheresis improved survival
in long-term follow-up (at 3, 5 and 8 years) when
compared with dialysed patients on the waiting list
or transplanted with an HLA-compatible kidney
[166]. 
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